Recombinant factor VIII-CVP therapy for acquired factor VIII inhibitors

DOI Web Site PubMed 1 Citations 15 References
  • MORI Naoki
    Department of Hematology, Tokyo Women's Medical University, School of Medicine
  • TOYOKAWA Kaoru
    Department of Hematology, Tokyo Women's Medical University, School of Medicine
  • TERAMURA Masanao
    Department of Hematology, Tokyo Women's Medical University, School of Medicine
  • MASUDA Michihiko
    Department of Hematology, Tokyo Women's Medical University, School of Medicine
  • MOTOJI Toshiko
    Department of Hematology, Tokyo Women's Medical University, School of Medicine

Bibliographic Information

Other Title
  • 第VIII因子インヒビターによる凝固障害に対する遺伝子組換え第VIII因子製剤—CVP療法
  • 症例報告 第8因子インヒビターによる凝固障害に対する遺伝子組換え第8因子製剤-CVP療法
  • ショウレイ ホウコク ダイ8 インシ インヒビター ニ ヨル ギョウコ ショウガイ ニ タイスル イデンシ クミカエ ダイ8 インシ セイザイ CVP リョウホウ

Search this article

Abstract

A 78-year-old man and an 81-year-old woman without hemophilia suddenly developed giant ecchymoses and intramuscular hemorrhage. Prolonged activated partial thromboplastin time and low factor VIII activity were observed, and the patients were subsequently diagnosed as having acquired factor VIII inhibitors. The patients were infused with one dose of recombinant factor VIII, 50 to 100 U/kg body weight, followed by cyclophosphamide, 500 mg on day 1 and 200 mg/day on days 2 to 5; vincristine, 2 mg on day 1; and prednisolone, 100 mg/day on days 1 to 5 (recombinant factor VIII-CVP therapy). Both patients responded after one course of therapy. Disappearance of inhibitors was achieved after three to four courses of therapy without subsequent recurrence. Recombinant factor VIII-CVP therapy is safe and effective in the eradication of factor VIII inhibitors.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 48 (7), 581-585, 2007

    The Japanese Society of Hematology

Citations (1)*help

See more

References(15)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top